Comprehensive review of potential drugs with anti-pulmonary fibrosis properties

Ma, Jie; Li, Gang; Wang, Han; Mo, Chunheng

doi:10.1016/j.biopha.2024.116282

Cited by 3 publications

(1 citation statement)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although therapeutic management of CD has improved with novel agents, an effective approach to address CD-related stricture continues to be elusive. Recent research has indicated that thyroid function is associated with fibrosis-related diseases, such as lung fibrosis ( 39 , 40 ) and liver fibrosis ( 41 , 42 ). Thyroid hormone has demonstrated efficacy in inhibiting lung fibrosis by enhancing epithelial mitochondrial function ( 43 ).…”

Section: Discussionmentioning

confidence: 99%

Casual associations of thyroid function with inflammatory bowel disease and the mediating role of cytokines

Wu,

Yi,

2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundPrevious observational epidemiological studies have suggested a potential association between thyroid function and inflammatory bowel disease (IBD). However, the findings remain inconclusive, and whether this association is causal remains uncertain. The objective of this study is to investigate the causal association between thyroid function and IBD.MethodsGenome-wide association studies (GWAS) involving seven indicators of thyroid function, IBD, and 41 cytokines were analyzed. Bidirectional two-sample Mendelian randomization (MR) and multivariable MR were conducted to examine the causal relationship between thyroid function and IBD and to explore the potential mechanisms underlying the associations.ResultsGenetically determined hypothyroidism significantly reduced the risk of CD (odds ratio [OR] = 0.761, 95% CI: 0.655–0.882, p < 0.001). Genetically determined reference-range TSH was found to have a suggestive causal effect on IBD (OR = 0.931, 95% CI: 0.888–0.976, p = 0.003), (Crohn disease) CD (OR = 0.915, 95% CI: 0.857–0.977, p = 0.008), and ulcerative colitis (UC) (OR =0.910, 95% CI: 0.830–0.997, p = 0.043). In reverse MR analysis, both IBD and CD appeared to have a suggestive causal effect on the fT3/fT4 ratio (OR = 1.002, p = 0.013 and OR = 1.001, p = 0.015, respectively). Among 41 cytokines, hypothyroidism had a significant impact on interferon-inducible protein-10 (IP-10) (OR = 1.465, 95% CI: 1.094–1.962, p = 0.010). The results of multivariable MR showed that IP-10 may mediate the causal effects of hypothyroidism with CD.ConclusionOur results suggest that an elevated TSH level reduces the risk of CD, with IP-10 potentially mediating this association. This highlights the pituitary-thyroid axis could serve as a potential therapeutic strategy for CD.

show abstract

Section: Discussionmentioning

confidence: 99%

Casual associations of thyroid function with inflammatory bowel disease and the mediating role of cytokines

Wu,

Yi,

2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

Response to antifibrotic therapy and decrease of circulating BAG3 protein levels in systemic sclerosis patients with reduced forced vital capacity

De Marco,

Basile,

Cammarota

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Highlights on Future Treatments of IPF: Clues and Pitfalls

Libra,

Sciacca,

Muscato

et al. 2024

IJMS

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by irreversible scarring of lung tissue, leading to death. Despite recent advancements in understanding its pathophysiology, IPF remains elusive, and therapeutic options are limited and non-curative. This review aims to synthesize the latest research developments, focusing on the molecular mechanisms driving the disease and on the related emerging treatments. Unfortunately, several phase 2 studies showing promising preliminary results did not meet the primary endpoints in the subsequent phase 3, underlying the complexity of the disease and the need for new integrated endpoints. IPF remains a challenging condition with a complex interplay of genetic, epigenetic, and pathophysiological factors. Ongoing research into the molecular keystones of IPF is critical for the development of targeted therapies that could potentially stop the progression of the disease. Future directions include personalized medicine approaches, artificial intelligence integration, growth in genetic insights, and novel drug targets.

show abstract

Comprehensive review of potential drugs with anti-pulmonary fibrosis properties

Cited by 3 publications

References 149 publications

Casual associations of thyroid function with inflammatory bowel disease and the mediating role of cytokines

Casual associations of thyroid function with inflammatory bowel disease and the mediating role of cytokines

Response to antifibrotic therapy and decrease of circulating BAG3 protein levels in systemic sclerosis patients with reduced forced vital capacity

Highlights on Future Treatments of IPF: Clues and Pitfalls

Contact Info

Product

Resources

About